Clinical Trial Update: Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ID93 + GLA-SE vaccination in participants with rifampicin-susceptible pulmonary tuberculosis. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• ID93 + GLA-SE vaccine

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: Tuberculosis, Pulmonary | Phase 2 | Status: NOT_YET_RECRUITING